《处方药使用者付费法案》：一个行动更快的食品药品监督管理局就一定是更好的食品药品监督管理局吗？ - Suppr

Suppr

超能文献

The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?

作者信息

Zelenay James L

出版信息

Food Drug Law J. 2005;60(2):261-338.

PMID:16094773

Abstract

摘要

相似文献

The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?

Food Drug Law J. 2005;60(2):261-338.

The Prescription Drug User Fee Act of 1992: speeding up the drug approval process.

Healthspan. 1992 Dec;9(11):12-4.

Drug safety reform at the FDA--pendulum swing or systematic improvement?

N Engl J Med. 2007 Apr 26;356(17):1700-2. doi: 10.1056/NEJMp078057. Epub 2007 Apr 13.

Paying for drug approvals--who's using whom?

N Engl J Med. 2007 Apr 26;356(17):1697-700. doi: 10.1056/NEJMp078041. Epub 2007 Apr 13.

PDUFA reauthorization--drug safety's golden moment of opportunity?

N Engl J Med. 2007 Apr 26;356(17):1703-4. doi: 10.1056/NEJMp078048. Epub 2007 Apr 13.

What ails the FDA?

N Engl J Med. 2005 Mar 17;352(11):1063-6. doi: 10.1056/NEJMp058003.

User fees and beyond--the FDA Safety and Innovation Act of 2012.

N Engl J Med. 2012 Oct 4;367(14):1277-9. doi: 10.1056/NEJMp1207800.

FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act.

J Law Med Ethics. 2006 Spring;34(1):131-4. doi: 10.1111/j.1748-720X.2006.00018.x.

The impact of FDA reform.

Med Device Technol. 2003 Apr;14(3):36-7.

Regulatory watch: impact of PDUFA on regulatory decision-making.

Nat Rev Drug Discov. 2010 Aug;9(8):585. doi: 10.1038/nrd3247.

引用本文的文献

The need for "gentle medicine" in a post Covid-19 world.

Med Health Care Philos. 2021 Dec;24(4):475-486. doi: 10.1007/s11019-021-10046-z. Epub 2021 Aug 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?

Food Drug Law J. 2005;60(2):261-338.

The Prescription Drug User Fee Act of 1992: speeding up the drug approval process.

Healthspan. 1992 Dec;9(11):12-4.

Drug safety reform at the FDA--pendulum swing or systematic improvement?

N Engl J Med. 2007 Apr 26;356(17):1700-2. doi: 10.1056/NEJMp078057. Epub 2007 Apr 13.

Paying for drug approvals--who's using whom?

N Engl J Med. 2007 Apr 26;356(17):1697-700. doi: 10.1056/NEJMp078041. Epub 2007 Apr 13.

PDUFA reauthorization--drug safety's golden moment of opportunity?

N Engl J Med. 2007 Apr 26;356(17):1703-4. doi: 10.1056/NEJMp078048. Epub 2007 Apr 13.

What ails the FDA?

N Engl J Med. 2005 Mar 17;352(11):1063-6. doi: 10.1056/NEJMp058003.

User fees and beyond--the FDA Safety and Innovation Act of 2012.

N Engl J Med. 2012 Oct 4;367(14):1277-9. doi: 10.1056/NEJMp1207800.

FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act.

J Law Med Ethics. 2006 Spring;34(1):131-4. doi: 10.1111/j.1748-720X.2006.00018.x.

The impact of FDA reform.

Med Device Technol. 2003 Apr;14(3):36-7.

Regulatory watch: impact of PDUFA on regulatory decision-making.

Nat Rev Drug Discov. 2010 Aug;9(8):585. doi: 10.1038/nrd3247.

引用本文的文献

The need for "gentle medicine" in a post Covid-19 world.

Med Health Care Philos. 2021 Dec;24(4):475-486. doi: 10.1007/s11019-021-10046-z. Epub 2021 Aug 20.